Biomark Diagnostics Inc (CSE:BUX)

0.6200 UNCHANGED

Streaming Delayed Price Updated: 3:50 PM EDT, Mar 11, 2026 Add to My Watchlist

Price and Volume

Volume	0
Open	0.6200
Bid (Size)	0.6000 (2,000)
Ask (Size)	0.6300 (2,000)
Prev. Close	0.6200
Today's Range	0.6200 - 0.6200
52wk Range	0.2400 - 0.6400
Shares Outstanding	N/A
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

BioMark Diagnostics Announces Publication of Peer-Reviewed Validation of Machine Learning Models for Lung Cancer Detection in Frontiers in Oncology

January 15, 2026

Vancouver, British Columbia--(Newsfile Corp. - January 15, 2026) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTCQB: BMKDF) ("BioMark"), a...

Via Newsfile

BioMark: 2025 Achievements & 2026 Vision

December 31, 2025

Vancouver, British Columbia--(Newsfile Corp. - December 31, 2025) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTCQB: BMKDF) ("BioMark" or the "Company"),...

Via Newsfile

Performance

YTD	+36.3%	+36.3%
1 Month	+24.0%	+24.0%
3 Month	+24.0%	+24.0%
6 Month	+69.9%	+69.9%
1 Year	+153.1%	+153.1%

More News

BioMark Diagnostics Announces Appointment of Mr. James Lavender to Board of Directors

December 30, 2025

Via Newsfile

BioMark Diagnostics Advances Commercialization Strategy by Initiating ISO 15189 Accreditation Program

December 23, 2025

Via Newsfile

BioMark Diagnostics Collaborative Lung Cancer Screening Project Honored by ADRIQ during the 35th Innovation Awards Gala

December 01, 2025

Via Newsfile

BioMark Aligns with National Strategy to Slash Lung Cancer Mortality with Next-Gen Liquid Biopsy

November 12, 2025

Via Newsfile

BioMark's Liquid Biopsy Platform Selected for Holistic German Lung Cancer Screening Trial

October 07, 2025

Via Newsfile

BioMark Secures Key Patents in Asia's Largest Markets for Early Lung Cancer Liquid Biopsy

September 29, 2025

Via Newsfile

BioMark Diagnostics Establishes African Market Presence Through Strategic Tunisia Healthcare Partnership

August 12, 2025

Via Newsfile

BioMark Announces Closing of $1.9 Million Non-Brokered Private Placement

December 29, 2023

Via Newsfile

BioMark Announces Recent New Patent Granted in Canada to Support Its Liquid Biopsy Based Legacy Assay

December 04, 2023

Via Newsfile

BioMark Provides Second Quarter Operational Update and Announces Extension to Warrant Exercise Term

November 28, 2023

Via Newsfile

BioMark Strengthens and Expands Its Strategic Advisory Team in Pursuit of Commercialization Initiatives

November 14, 2023

Via Newsfile

BioMark Announces Financial Contribution from the City of Quebec to Support Commercialization Initiatives of Its Proprietary Lung Cancer Detection Test

November 07, 2023

Via Newsfile

BioMark to Unveil Results of Its Early Breast Cancer Study at the Upcoming San Antonio Breast Cancer Symposium

October 24, 2023

Via Newsfile

BioMark Appoints Kevin J. Cosgriff to Its Strategic Advisory Team

August 30, 2023

Via Newsfile

Japan Patent Office (JPO) Issued BioMark Patent with Claims Covering Its Lung Cancer Urine Based Liquid Biopsy Assay

August 08, 2023

Via Newsfile

BioMark Unveils Significant Scientific Advancements from Its Leading Liquid Biopsy Technology at ASCO 2023 Annual Meeting

June 05, 2023

Via Newsfile

BioMark Announces the U.S. Patent and Trademark Office Granted Patent with Claims Covering Its Lung Cancer Liquid Biopsy Assay

May 31, 2023

Via Newsfile

BioMark Latest Results Accepted for Presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting 2023

May 03, 2023

Via Newsfile

BioMark Presents Novel Liquid Biopsy Data in Pulmonary Neuroendocrine Tumors

March 16, 2023

Via Newsfile

Biomark Receives Funding Supporting Research and Development Project for Cancer Treatment Monitoring

February 07, 2023

Via Newsfile

BioMark Announces Update from Ongoing Clinical Trial Using Its Lung Cancer Liquid Biopsy Test as It Prepares for Commercial Launch

January 11, 2023

Via Newsfile

BioMark to Collaborate with Astrazeneca, Pfizer Canada and The IUCPQ Foundation in a $3.5m Project to Improve Early Detection of Lung Cancer

November 30, 2021

Via Newsfile

Liquid Biopsy Company BioMark to Present at the 3rd Annual Congress of the International Society of Liquid Biopsy to Be Held October 22, 2021

October 18, 2021

Via Newsfile

Frequently Asked Questions

Is Biomark Diagnostics Inc publicly traded?

Yes, Biomark Diagnostics Inc is publicly traded.

What exchange does Biomark Diagnostics Inc trade on?

Biomark Diagnostics Inc trades on the Canadian Securities Exchange

What is the ticker symbol for Biomark Diagnostics Inc?

The ticker symbol for Biomark Diagnostics Inc is BUX on the Canadian Securities Exchange

What is the current price of Biomark Diagnostics Inc?

The current price of Biomark Diagnostics Inc is 0.6200

When was Biomark Diagnostics Inc last traded?

The last trade of Biomark Diagnostics Inc was at 03/11/26 03:50 PM ET

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.